Fresensius Kabi USA, LLC
NDC labeler code: 63323
What is a labeler?
The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.
Official FDA data only
Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.
Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.
Prescription medicines
- PosaconazoleNoxafil · 1 product
FDA applications for these products
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Approved | Application | Medicine | Sponsor |
|---|---|---|---|
| December 26, 2023 | ANDA209983 | Posaconazole POSACONAZOLE | Fresenius Kabi USA |
The sponsor is the company that holds the FDA application; it can differ from the labeler.
Recall timeline
2026
-
July 16, 2026 · Class II · Ongoing · D-0727-2026 · Ropivacaine hydrochloride
Presence of Particulate Matter: Hair was found in products
Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-0
-
July 16, 2026 · Class II · Ongoing · D-0725-2026 · Glycopyrrolate
Presence of Particulate Matter: Hair was found in product
Glycopyrrolate Injection, USP, 1 mg per 5 mL (0.2 mg per mL), 25 x 5 mL fill in a 6.5 mL vial, Rx only, Multiple Dose Vials, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-578-05; NDC Vial: 63323-578-07
-
July 16, 2026 · Class II · Ongoing · D-0726-2026 · Lidocaine
Presence of Particulate Matter: Hair was found in products
Lidocaine HCl Injection, USP, 2%, 100 mg per 5 mL (20 mg per mL), 25 Single Dose Vials, 5 mL per vial, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-208-05; NDC Vial: 63323-208-01
-
July 16, 2026 · Class II · Ongoing · D-0728-2026 · Lidocaine hydrochloride,epinephrine bitartrate, Lidocaine
Presence of Particulate Matter: Hair was found in products
Xylocaine (lidocaine HCl Injection, USP), 1%, 200 mg per 20 mL (10 mg per mL), 25 Multiple-Dose Vials, 20 mL, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-485-27; NDC Vial: 63323-485-01
-
July 16, 2026 · Class II · Ongoing · D-0729-2026 · Lidocaine hydrochloride,epinephrine bitartrate, Lidocaine
Presence of Particulate Matter: Hair was found in products
Xylocaine (lidocaine HCl Injection, USP), 1%, 500 mg per 50 mL (10 mg per mL), 25 Multiple-Dose Vials, 50 mL, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-485-57; NDC Vial: 63323-485-03
-
May 14, 2026 · Class III · Ongoing · D-0581-2026 · Epinephrine
Failed Impurities/Degradations Specifications
Epinephrine Injection, USP, 1mg/mL, 1 mL single-dose vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047, NDC 63323-696-02 (vial), NDC 63323-696-25 (carton)
-
March 11, 2026 · Class II · Ongoing · D-0424-2026 · Sodium chloride
Lack of Assurance of Sterility
0.45% Sodium Chloride Injection, USP, 1.125 grams per 250 mL (4.5 mg per mL), 250 mL in a 250 mL freeflex bag, Rx only, Fresenius Kabi USA, LLC ("Fresenius Kabi"), Lake Zurich, IL 60047, Unit of Use NDC: 63323-626-03, Un
2025
-
November 6, 2025 · Class I · Ongoing · D-0182-2026 · Famotidine
Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.
Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL vials, Rx only, Fresenius Kabi USA, LLC, NDC 63323-739-11 (unit of use), 63323-739-12 (unit of sale).
2022
-
November 22, 2022 · Class II · Terminated · D-0127-2023 · Bupivacaine hydrochloride and epinephrine bitartrate, Bupivacaine hydrochloride
Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.
Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 125 mg per 50 mL (2.5 mg per mL), 50 mL Multiple Dose Vial (NDC 63323-461-01), packaged in 25 Multiple Dose
-
November 22, 2022 · Class II · Terminated · D-0129-2023 · Bupivacaine hydrochloride and epinephrine bitartrate, Bupivacaine hydrochloride
Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.
Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 25 mg per 10 mL (2.5 mg per mL), 10 mL Single Dose Vial (NDC 63323-468-01), packaged in 25 Single Dose V
Show the 44 older recalls
2022
-
November 22, 2022 · Class II · Terminated · D-0128-2023 · Bupivacaine hydrochloride and epinephrine bitartrate, Bupivacaine hydrochloride
Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.
Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.5%, 250 mg per 50 mL (5 mg per mL), 50 mL Multiple Dose Vial (NDC 63323-463-01), packaged in 25 Multiple Dose Via
-
April 13, 2022 · Class II · Terminated · D-1116-2022 · Propofol
cGMP deviations: Temperature abuse
Diprivan (Propofol) Emulsion, 200 mg per 20 mL (10mg/mL), 20 mL vial, Rx only, MFG: App Pharmaceutical LLC, NDC 63323-269-29
-
April 13, 2022 · Class II · Terminated · D-1052-2022 · Lidocaine hydrochloride,epinephrine bitartrate, Lidocaine
cGMP deviations: Temperature abuse
Xylocaine + Epinephrine, multi dose vial 1%, packaged in a) 20 mL, 25-count box (NDC 63323-482-27) b) 50 mL, 25-count box (NDC 63323-482-57), Rx only, MFG: Fresenius Kabi USA LLC
-
April 13, 2022 · Class II · Terminated · D-1115-2022 · Propofol
cGMP deviations: Temperature abuse
Diprivan (Propofol) Emulsion, 100 mg/mL, 10mL vial, Rx only, MFG: App Pharmaceutical LLC, NDC 63323-269-10
-
April 13, 2022 · Class II · Terminated · D-1053-2022 · Lidocaine hydrochloride,epinephrine bitartrate, Lidocaine
cGMP deviations: Temperature abuse
Xylocaine + Epinephrine, multi dose vial 2%, 20 mL, 25 count box, Rx only, MFG: Fresenius Kabi USA LLC, NDC 63323-483-27
-
March 4, 2022 · Class I · Terminated · D-0750-2022 · Sodium acetate
Presence of particulate matter: particulates composed of carbon and oxygen with varying amounts of iron and trace amounts of sodium, silicon, chromium, aluminum and cellulose.
Sodium Acetate Injection, USP, 400 mEq / 100 mL (4 mEq / mL), packaged in 2 trays of 20 vials per shipper (NDC 63323-032-00), each vial: 100 mL fill in a 100 mL vial (NDC 63323-032-04), Rx Only, Fresenius Kabi, Lake Zuri
2021
-
September 17, 2021 · Class II · Terminated · D-0856-2021 · Morphine sulfate
Defective container: Cracked vials leading to lack of sterility assurance
Morphine Sulfate Injection, USP, 2 mg per mL, 1 mL single dose vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047, NDC 63323-452-01. 25 vials per tray packaged 18 trays per shipper
-
June 25, 2021 · Class II · Terminated · D-0651-2021 · Lidocaine hydrochloride,epinephrine bitartrate, Lidocaine
Low out of specification results for epinephrine assay.
Xylocaine-MPF with Epinephrine 1:200,000, (Lidocaine HCl and Epinephrine Injection, USP), 1%, 300 mg/30 mL, (10 mg/mL), 30 mL Single Dose Vial, 25 Vials per Tray, Rx only, Fresenius Kabi USA, LLC, Lake Zurich, IL 60047.
2020
-
December 23, 2020 · Class I · Terminated · D-0245-2021 · Ketorolac tromethamine
Presence of Particulate Matter - found in reserve sample vials at the firm.
Ketorolac Tromethamine Injection, USP, 30 mg per mL, packaged in 1 mL Single Dose Vials (NDC 63323-162-00); 25 x 1 mL Single Dose Vials per tray (NDC 63323-162-01); For IM or IV use, Rx only, Fresenius Kabi, Lake Zurich,
-
December 17, 2020 · Class II · Terminated · D-0184-2021 · Ketorolac tromethamine
Presence of Particulate Matter - found in reserve sample vials at the firm.
Ketorolac Tromethamine Injection, USP, 60 mg per 2 mL (30 mg per mL), packaged in 2 mL Single Dose Vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047, NDC 63323-162-02
-
December 10, 2020 · Class II · Terminated · D-0172-2021 · Bupivacaine hydrochloride and epinephrine bitartrate, Bupivacaine hydrochloride
Subpotent Drug: Low out-of-specification assay results for the epinephrine component.
Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP), 0.5%, 150 mg per 30 mL (5 mg per mL), 30 mL Single Dose Vial (NDC 63323-462-01), packaged as 25 Single Dose Vials per tray (NDC 63323-462-37), Rx only, Fr
-
November 17, 2020 · Class III · Terminated · D-0105-2021 · Doxorubicin hydrochloride
Cross Contamination with Other Products: trace amounts of octreotide found during testing
DOXOrubicin Hydrochloride Injection, USP, 10 mg / 5 mL (2 mg / mL), 5 mL fill in a 6 mL vial, Single Dose Vial, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047. NDC: 63323-883-05
-
July 13, 2020 · Class III · Terminated · D-1391-2020 · Fosaprepitant
Labeling Error: Label Error on Declared Strength: Carton label and product insert incorrectly states the quantity of the excipient edetate disodium (EDTA) as 5.4 mg / vial, rather than the actual amount of 18.8 mg / vial.
Fosaprepitant for Injection, 150 mg / vial in a 10 mL Single-Dose vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047; NDC 63323-972-10
-
June 17, 2020 · Class III · Terminated · D-1392-2020 · Famotidine
TEMPERATURE ABUSE: Complaint received from customer that product was received in a non-refrigerated state.
Famotidine Injection, USP, 20 mg/2mL, 2 mL vial, Rx only, Single Dose Vial, For Intravenous Use Only After Dilution, Distributed by HF Acquisition Co, LLC, Mukilteo, WA 98275, NDC 63323-739-12
-
April 20, 2020 · Class I · Terminated · D-1296-2020 · Ketorolac tromethamine
Presence of Particulate Matter - found in reserve sample vials at the firm.
Ketorolac Tromethamine Injection, USP, 30 mg per mL, packaged in 1 mL Single Dose Vials (NDC 63323-162-00); 25 x 1 mL Single Dose Vials per tray (NDC 63323-162-01); For IM or IV use, Rx only, Fresenius Kabi, Lake Zurich,
-
April 20, 2020 · Class II · Terminated · D-1297-2020 · Ketorolac tromethamine
Presence of Particulate Matter - found in reserve sample vials at the firm.
Ketorolac Tromethamine Injection, USP, 60 mg per 2 mL (30 mg per mL), packaged in 2 mL Single Dose Vials (NDC 63323-162-03), 25 x 2 mL Single Dose Vials per tray (NDC 63323-162-02); For IM use only, Not for IV use, Rx on
2019
-
June 28, 2019 · Class I · Terminated · D-1489-2019 · Fluorouracil
Presence of Particulate Matter; glass particulates
Fluorouracil Injection, USP, 5 g / 100 mL (50 mg / mL), 100 mL fill in a 100 mL vial, Rx Only, Mfd. by: Fresenius Kabi, Lake Zurich, IL 60047. 63323-117-61 [Fresenius Kabi brand] and NDC 63323-117-69 [NOVAPLUS brand]
-
May 22, 2019 · Class III · Terminated · D-1386-2019 · Ondansetron
Failed Impurities/Degradation Specifications.
Ondansetron Injection, USP, 40 mg / 20 mL, 20 mL vial, Rx Only, Fresenius Kabi USA, LLC, Lake Zurich, IL 60047, NDC 63323-374-20
2018
-
November 15, 2018 · Class I · Terminated · D-0298-2019 · Sodium chloride
Labeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect statement on the product insert for product codes 918610 and 918620 indicating that the stoppers do not contain natural rubber latex. The tray label for these two product codes and the vial label for product code 918620 also inc
SODIUM CHLORIDE INJECTION, USP, 0.9%, 10 mL Single Dose Vial, packaged in a 25-unit tray, Rx Only, APP Pharmaceuticals, LLC Schaumburg, IL 60173. NDC 63323-186-10 Product code 918610
-
November 15, 2018 · Class I · Terminated · D-0299-2019 · Sodium chloride
Labeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect statement on the product insert for product codes 918610 and 918620 indicating that the stoppers do not contain natural rubber latex. The tray label for these two product codes and the vial label for product code 918620 also inc
SODIUM CHLORIDE INJECTION, USP, 0.9%, 20 mL Single Dose Vial, packaged in a 25-unit tray, Rx Only, APP Pharmaceuticals, LLC Schaumburg, IL 60173. NDC 63323-186-20, Product code 918620
2017
-
March 8, 2017 · Class II · Terminated · D-0668-2017 · Hydralazine hydrochloride
Temperature Abuse: Certain pieces of these lots distributed by McKesson Medical Surgical Inc. were inadvertently stored refrigerated rather than the labeled room temperature recommendation.
hydrALAZINE HYDROCHLORIDE INJECTION, USP, 20 mg/mL, 1 mL Single Dose Vial, packaged in 25 Vials per carton, Rx only, APP Fresenius Kabi USA, LLC, Lake Surich, IL 60047, NDC 63323-614-01, Distributed by McKesson Medical-S
2016
-
December 16, 2016 · Class II · Terminated · D-0456-2017 · Midazolam
Failed Impurities/Degradation Specifications
MIDAZOLAM INJECTION, USP, *25 mg/5 mL, (5 mg/ mL), 5 mL vials, 10 Vials per carton, Rx only, APP Pharmaceuticals, LLC Schaumburg, IL 60173 --- NDC 63323-412-05
-
April 25, 2016 · Class II · Terminated · D-1037-2016 · Bupivacaine hydrochloride and epinephrine bitartrate, Bupivacaine hydrochloride
Presence of Particulate Matter: Glass particulate found in sterile injectable product
Sensorcaine- MPF (Bupivacaine HCI Injection, USP), 0.75% in a 30 mL Single Dose Vial, Rx only, Fresenius Kabi USA LLC, Lake Zurich, IL 60047, NDC 63323-472-37
-
April 7, 2016 · Class III · Terminated · D-0818-2016 · Haloperidol decanoate
Failed Impurities/Degradation Specifications: Firm is recalling product due to an impurity out-of-specification result.
Haloperidol Decanoate Injection, 50 mg/mL, 1 mL vial, Rx Only. Fresenius Kabi USA LLC, Lake Zurich, IL 60047, NDC 63323-469-01.
-
April 5, 2016 · Class II · Terminated · D-0819-2016 · Cisatracurium besylate
Incorrect/ Undeclared Excipient: Firm is recalling product due to an incorrect statement of Preservative free on the individual carton label. The vial label and outer carton label contain the correct statement of 0.9% benzyl alcohol added as a preservative.
Cisatracurium Besylate Injection, 20 mg per 10 mL (2 mg per mL), For intravenous injection, 10 mL Multiple Dose Vial, Rx only, Fresenius Kabi USA, LLC Lake Zurich, IL 60047, NDC 63323-417-10
2015
-
July 28, 2015 · Class III · Terminated · D-1327-2015 · Hydralazine hydrochloride
Incorrect Expiration Date: The "11/06" expiration date printed on the tray (secondary packaging) is incorrect (it should be 11/2016)
Hydralazine Hydrochloride Injection, USP, 20 mg/mL, 1 mL fill, in a 2 mL; single dose vial. Manufactured by Fresenius Kabi USA 2020 N Ruby Street, Melrose Park, IL 60160-1112 for Fresenius Kabi USA, 3 Corporate Dr Lake Z
-
June 4, 2015 · Class II · Terminated · D-1234-2015 · Rifampin
Failed Impurities/Degradation Specifications; out-of-specification for color, impurity, and degradation
Rifampin for Injection, USP 600mg/vial in a 20mL vial, Rx only, Manufactured for Fresenius Kabi LLC 3 Corporate Drive, Lake Zurich, IL, 60047, by Fresenius Kabi LLC, 2020 N Ruby Street, Melrose Park, IL 60160. NDC 63323-
-
April 28, 2015 · Class II · Terminated · D-1114-2015 · Dextrose, soybean oil, electrolytes, lysine, phenylalanine, leucine, valine, threonine, methionine, isoleucine, tryptophan, alanine, arginine, glycine, proline, histidine, glutamic acid, serine, aspartic acid and tyrosine
Labeling: Label Error on Declared Strength: Labeled 3.1% Amino Acids but contains 3.3% Amino Acids
KABIVEN [(3.9%) Lipid Injectable Emulsion with (3.1%) Amino Acids and Electrolytes and (9.8%) Dextrose; Sulfite-free], Rx Only. Manufactured by: FRESENIUS KABI Uppsala, Sweden. Packaged in 1) 1,540 mL Bags, NDC: 63323-71
2014
-
November 12, 2014 · Class II · Terminated · D-0290-2015 · Gentamicin sulfate
Defective Container: Vials may be missing stoppers.
GENTAMICIN INJECTION, USP, equivalent to 40 mg/mL, Rx only, 20 mL Multiple Dose Vial, Manufactured by APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-010-20
-
August 13, 2014 · Class II · Terminated · D-1545-2014 · Propranolol hydrochloride
CGMP Deviations: Citations given to API supplier by the Italian Health Agency AIFA for several critical deficiencies which caused a recall of the API lot used to manufacture Propanolo HCl Injection.
PROPRANOLOL HYDROCHLORIDE INJECTION, USP 1 mg/mL, 1 mL Single Dose Vial, Rx only, APP Pharmaceuticals, LLC Schaumburg, IL 60173, NDC 63323-604-01
-
May 2, 2014 · Class II · Terminated · D-1429-2014 · Fosphenytoin sodium
Presence of Particular Matter: Potential glass delamination and consistent with glass particulates observed in sample vials.
Fosphenytoin Sodium Injection, USP, 500 mg PE/10 mL (50 mg PE/mL), (PE= phenytoin sodium equivalents) 10 mL Single Use Vial, Rx only, Manufactured for APP Fresenius Kabi USA, LLC Lake Zurich, IL 60047, NDC 63323-403-10
-
May 2, 2014 · Class II · Terminated · D-1428-2014 · Fosphenytoin sodium
Presence of Particular Matter: Potential glass delamination and consistent with glass particulates observed in sample vials.
Fosphenytoin Sodium Injection, USP, 100 mg PE/2 mL (50 mg PE/mL) (PE= phenytoin sodium equivalents) 2 mL Single Use Vial, Rx only, Manufactured for APP Fresenius Kabi USA, LLC Lake Zurich, IL 60047, NDC 63323-403-02
-
April 14, 2014 · Class III · Terminated · D-0247-2015 · Haloperidol decanoate
Failed Impurities/Degradation Specifications: Fresenius Kabi is recalling three lots of Haloperidol Decanoate Injection due to an out-of-specification result.
HALOPERIDOL DECANOATE INJECTION, 50 mg/mL, 1 mL vial, Rx only, Fresenius Kabi USA, LLC, Schaumburg, IL 60173 NDC 63323-469-01
-
January 22, 2014 · Class II · Terminated · D-1148-2014 · Heparin sodium
Subpotent; 18 month time point
Heparin Sodium Injection, USP 10,000 USP units per 10 mL (1,000 USP units per mL) For IV or SC use, Multi-Dose Vial, Rx only, NDC 63323-540-11, 25 vials in tray, each boxed vial individually labeled as: Heparin Sodium In
2013
-
December 6, 2013 · Class III · Terminated · D-379-2014 · Folic acid
Failed Impurities/Degradation specifications: out-of-specification results 14 & 15 month time point
FOLIC ACID INJECTION, USP; 5 mg/mL ; For IM, IV or SC Use; 10 mL; Multiple Dose Vial; Rx only; APP Pharmaceuticals, LLC; Schaumburg, IL 60173 NDC 63323-184-11
-
November 8, 2013 · Class III · Terminated · D-016-2014 · Paclitaxel
Labeling: Incorrect or Missing Package Insert- Missing text on the product insert in the "Clinical Studies" and "Specific Adverse Events" sections.
PACLITAXEL INJECTION, USP (semisynthetic); 300 mg/50 mL; (6 mg/mL); Multiple Dose Vial;(NDC 63323-763-50); Rx Only; Manufactured for APP Pharmaceuticals, LLC; Schaumburg, IL 60173; Made in India
-
July 1, 2013 · Class II · Terminated · D-685-2013 · Benztropine mesylate
Presence of particulate matter: characterized as thin colorless flakes that are visually and chemically consistent with glass delamination observed in reserve sample vials
Benztropine Mesylate Injection, USP, 2 mg/2 mL (1 mg/1 mL), 2 mL Single Dose Vial, Rx only, labeled as a) Manufactured for: APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-970-02; and b) Manufactured in the USA
-
June 24, 2013 · Class II · Terminated · D-804-2013 · Oxytocin
Subpotent Drug; 15-month stability test station
Oxytocin Injection, USP, (Synthetic), 10 USP Units/mL, for IV Infusion or IM Use, Rx Only, 1 mL vial, APP ) 10 USP Units/mL, 1 mL, APP Pharmaceuticals, LLC Schaumburg, IL, 60173, NDC 63323-012-01.
-
May 25, 2013 · Class I · Terminated · D-920-2013 · Magnesium sulfate heptahydrate
Presence of Particulate Matter: Glass particulate matter was observed in a retention sample during an annual review.
Magnesium Sulfate Injection, USP, 50% (25 grams/50 mL), For IM or IV Use, 50 mL, Single Dose Vial, Rx only, Preservative Free, APP Pharmaceuticals, LLC, Schaumburg, IL, 60173, NDC 63323-064-50
-
May 21, 2013 · Class III · Terminated · D-688-2013 · Folic acid
Failed Impurities/Degradation Specification
Folic Acid Injection, USP, 5 mg/mL, For IM, IV or SC Use, 10 mL, Multiple Dose Vial, Rx only, APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-184-11
-
January 22, 2013 · Class II · Terminated · D-915-2013 · Irinotecan hydrochloride
Crystallization: Active pharmaceutical ingredient is precipitating in product solution.
IRINOTECAN HYDROCHLORIDE INJECTION, 40 mg/2 mL (20 mg/mL), 2 mL Single Dose Vial, Rx only, Manufactured for: APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-193-02, UPC 3 63323 19302 7.
2012
-
September 27, 2012 · Class II · Terminated · D-0296-2015 · Ondansetron
Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles.
ONDANSETRON INJECTION, USP, 4 mg/ 2 mL (2 mg/mL), For IM or IV Use, Single Dose 2 mL Vials, Rx only. APP Pharmaceuticals, LLC, Schaumburg, IL 60173. NDC: 63323-373-02
-
September 27, 2012 · Class II · Terminated · D-0297-2015 · Cyanocobalamin
Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles.
CYANOCOBALAMIN INJECTION, USP, 1000 mcg/mL, For IM or IV Use, Multiple Dose 2 mL Vials, Rx only. APP Pharmaceuticals, LLC, Schaumburg, IL 60173. NDC: 63323-044-01.
-
September 27, 2012 · Class II · Terminated · D-0295-2015 · Midazolam
Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles.
MIDAZOLAM HYDROCHLORIDE INJECTION, 5 mg/1 mL, C-IV, For IM or IV Use, 2 mL Vials, Rx only. APP Pharmaceuticals, LLC. Schaumburg, IL 60173. NDC: 63323-412-25.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Next steps
- Find a pharmacy near youAsk which company made your medicine and whether it is recalled
- Latest FDA drug recallsAll companies, newest first
- All drug companiesA to Z
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026